Change the face of postsurgical recovery
EXPAREL provides significant long-lasting pain control while reducing opioid use
New data versus bupivacaine HCl2
reduction in overall opioid consumption
reduction in cumulative pain scores
Results from an EXPAREL Phase 4, double-blind, randomized controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA. Primary endpoints: area under the curve of visual analog scale pain intensity scores 12–48 hours postsurgery; total opioid consumption 0–48 hours postsurgery. Rescue opioids for pain were available upon patient request.
The OR and PACU are potential gateways to long-term opioid use
Minimizing opioid use is a widely supported practice, but the majority of surgical patients still receive an opioid.3,4